ZA965868B - Farnesyl transferase inhibitors their preparation and pharmaceutical compositions comprising them - Google Patents
Farnesyl transferase inhibitors their preparation and pharmaceutical compositions comprising themInfo
- Publication number
- ZA965868B ZA965868B ZA965868A ZA965868A ZA965868B ZA 965868 B ZA965868 B ZA 965868B ZA 965868 A ZA965868 A ZA 965868A ZA 965868 A ZA965868 A ZA 965868A ZA 965868 B ZA965868 B ZA 965868B
- Authority
- ZA
- South Africa
- Prior art keywords
- preparation
- pharmaceutical compositions
- transferase inhibitors
- farnesyl transferase
- farnesyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/72—4,7-Endo-alkylene-iso-indoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9508296A FR2736641B1 (fr) | 1995-07-10 | 1995-07-10 | Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA965868B true ZA965868B (en) | 1997-01-29 |
Family
ID=9480830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA965868A ZA965868B (en) | 1995-07-10 | 1996-07-10 | Farnesyl transferase inhibitors their preparation and pharmaceutical compositions comprising them |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US5936097A (cs) |
| EP (1) | EP0839133B1 (cs) |
| JP (1) | JPH11511123A (cs) |
| KR (1) | KR19990028856A (cs) |
| CN (1) | CN1096448C (cs) |
| AR (1) | AR003143A1 (cs) |
| AT (1) | ATE185341T1 (cs) |
| AU (1) | AU712194B2 (cs) |
| BR (1) | BR9609440A (cs) |
| CA (1) | CA2224414A1 (cs) |
| CO (1) | CO4700457A1 (cs) |
| CZ (1) | CZ291620B6 (cs) |
| DE (1) | DE69604588T2 (cs) |
| DK (1) | DK0839133T3 (cs) |
| EA (1) | EA000797B1 (cs) |
| ES (1) | ES2139373T3 (cs) |
| FR (1) | FR2736641B1 (cs) |
| GR (1) | GR3031409T3 (cs) |
| IL (1) | IL122812A (cs) |
| MA (1) | MA23929A1 (cs) |
| MX (1) | MX9800262A (cs) |
| MY (1) | MY114792A (cs) |
| NO (1) | NO309565B1 (cs) |
| NZ (1) | NZ313211A (cs) |
| PE (1) | PE11898A1 (cs) |
| PL (1) | PL324430A1 (cs) |
| SK (1) | SK282250B6 (cs) |
| TN (1) | TNSN96098A1 (cs) |
| TW (1) | TW438792B (cs) |
| UY (1) | UY24276A1 (cs) |
| WO (1) | WO1997003050A1 (cs) |
| ZA (1) | ZA965868B (cs) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2757855B1 (fr) * | 1996-12-30 | 1999-01-29 | Rhone Poulenc Rorer Sa | Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent |
| US6013662A (en) * | 1996-12-30 | 2000-01-11 | Rhone-Poulenc Rorer S.A. | Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments |
| US6124465A (en) * | 1997-11-25 | 2000-09-26 | Rhone-Poulenc S.A. | Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments |
| JP2001527078A (ja) * | 1997-12-23 | 2001-12-25 | アベンテイス・フアルマ・ソシエテ・アノニム | 新規なファルネシルトランスフェラーゼインヒビター、それらの製造、それらを含有する製薬学的組成物及び医薬品の製造のためのそれらの使用 |
| FR2772764B1 (fr) * | 1997-12-23 | 2000-01-14 | Rhone Poulenc Rorer Sa | Nouveaux inhibiteurs de farnesyle transferase, leur preparation, les compositions pharmaceutiques qui les contiennent et leur utilisation pour la preparation de medicaments |
| FR2787327B1 (fr) * | 1998-12-21 | 2003-01-17 | Aventis Pharma Sa | Compositions contenant des inhibiteurs de farnesyle transferase |
| FR2796641B1 (fr) | 1999-07-22 | 2001-09-21 | Aventis Pharma Sa | Nouveau procede de preparation de composes benzoperhydroisoindole |
| US20020177575A1 (en) * | 2001-05-04 | 2002-11-28 | Ward Wakeland | Identification of farnesyl-protein transferase as a target for systemic lupus erythematosus therapies |
| EP1888050B1 (en) | 2005-05-17 | 2012-03-21 | Merck Sharp & Dohme Ltd. | cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid for the treatment of cancer |
| TWI387592B (zh) | 2005-08-30 | 2013-03-01 | Novartis Ag | 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法 |
| GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| RS56600B1 (sr) | 2006-04-19 | 2018-02-28 | Novartis Ag | 6-o-supstituisana jedinjenja benzoksazola i benzotiazola i postupci inhibicije csf-1r signalinga |
| EP2698157B1 (en) | 2006-09-22 | 2015-05-20 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| SI2805945T1 (sl) | 2007-01-10 | 2019-09-30 | Msd Italia S.R.L. | Amid substituirani indazoli, kot inhibitorji poli(ADP-riboza)polimeraze(PARP) |
| AU2008221263B2 (en) | 2007-03-01 | 2012-02-23 | Novartis Ag | Pim kinase inhibitors and methods of their use |
| BRPI0812159A2 (pt) | 2007-05-21 | 2017-05-02 | Novartis Ag | inibidores de csf-1r, composições e métodos de uso |
| JP5501227B2 (ja) | 2007-06-27 | 2014-05-21 | メルク・シャープ・アンド・ドーム・コーポレーション | ヒストンデアセチラーゼ阻害剤としての４−カルボキシベンジルアミノ誘導体 |
| US7932036B1 (en) | 2008-03-12 | 2011-04-26 | Veridex, Llc | Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase |
| WO2010114780A1 (en) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| WO2010144909A1 (en) | 2009-06-12 | 2010-12-16 | Novartis Ag | Fused heterocyclic compounds and their uses |
| EA023838B1 (ru) | 2009-10-14 | 2016-07-29 | Мерк Шарп Энд Домэ Корп. | ЗАМЕЩЕННЫЕ ПИПЕРИДИНЫ, КОТОРЫЕ ПОВЫШАЮТ АКТИВНОСТЬ p53, И ИХ ПРИМЕНЕНИЕ |
| EP2937345B1 (en) | 2009-12-29 | 2018-03-21 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| JP2013522292A (ja) | 2010-03-16 | 2013-06-13 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | インダゾール化合物およびそれらの使用 |
| WO2011163330A1 (en) | 2010-06-24 | 2011-12-29 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
| CA2806112C (en) | 2010-07-28 | 2023-03-21 | Veridex, Llc | Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase inhibitors |
| US8518907B2 (en) | 2010-08-02 | 2013-08-27 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA) |
| RU2745848C2 (ru) | 2010-08-17 | 2021-04-01 | Сирна Терапьютикс, Инк. | ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК) |
| US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
| EP2613782B1 (en) | 2010-09-01 | 2016-11-02 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
| US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
| US9260471B2 (en) | 2010-10-29 | 2016-02-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
| US9351965B2 (en) | 2010-12-21 | 2016-05-31 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
| US20140045847A1 (en) | 2011-04-21 | 2014-02-13 | Piramal Enterprises Limited | Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation |
| WO2013063214A1 (en) | 2011-10-27 | 2013-05-02 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| AU2012340200B2 (en) | 2011-11-17 | 2017-10-12 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-Jun-N-Terminal Kinase (JNK) |
| EP3358013B1 (en) | 2012-05-02 | 2020-06-24 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (sina) compositions |
| JP6280554B2 (ja) | 2012-09-28 | 2018-02-14 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Ｅｒｋ阻害剤である新規化合物 |
| EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| WO2014063061A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| US10000483B2 (en) | 2012-10-19 | 2018-06-19 | Dana-Farber Cancer Institute, Inc. | Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof |
| PT2925888T (pt) | 2012-11-28 | 2017-12-13 | Merck Sharp & Dohme | Composições e métodos para tratamento do cancro |
| EP2935263B1 (en) | 2012-12-20 | 2018-12-05 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
| WO2014120748A1 (en) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| EP3057956B1 (en) | 2013-10-18 | 2021-05-05 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7) |
| AU2014337122B2 (en) | 2013-10-18 | 2019-01-03 | Dana-Farber Cancer Institute, Inc. | Heteroaromatic compounds useful for the treatment of proliferative diseases |
| WO2015164614A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
| US9862688B2 (en) | 2014-04-23 | 2018-01-09 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
| JO3589B1 (ar) | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
| AU2015371251B2 (en) | 2014-12-23 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| US10550121B2 (en) | 2015-03-27 | 2020-02-04 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| CA2986441A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| ES2741782T3 (es) | 2015-08-17 | 2020-02-12 | Kura Oncology Inc | Métodos para tratar pacientes con cáncer a partir de inhibidores de la farnesiltransferasa |
| US11142507B2 (en) | 2015-09-09 | 2021-10-12 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| JOP20190055A1 (ar) | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | أجسام مضادة ضد cd27 |
| US10975084B2 (en) | 2016-10-12 | 2021-04-13 | Merck Sharp & Dohme Corp. | KDM5 inhibitors |
| SG11201903786UA (en) | 2016-11-03 | 2019-05-30 | Kura Oncology Inc | Farnesyltransferase inhibitors for use in methods of treating cancer |
| CN118267470A (zh) | 2017-04-13 | 2024-07-02 | 赛罗帕私人有限公司 | 抗SIRPα抗体 |
| WO2019094311A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| US11098059B2 (en) | 2017-11-08 | 2021-08-24 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
| WO2019113269A1 (en) | 2017-12-08 | 2019-06-13 | Kura Oncology, Inc. | Methods of treating cancer patients with farnesyltransferase inhibitors |
| WO2019148412A1 (en) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
| AU2019295632B2 (en) | 2018-06-25 | 2025-03-06 | Dana-Farber Cancer Institute, Inc. | Taire family kinase inhibitors and uses thereof |
| EP3833667B1 (en) | 2018-08-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| CA3108388A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| US11993602B2 (en) | 2018-08-07 | 2024-05-28 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| CN113557017B (zh) | 2018-12-28 | 2024-11-29 | 丹娜-法伯癌症研究院 | 细胞周期蛋白依赖性激酶7的抑制剂及其用途 |
| WO2020190604A1 (en) | 2019-03-15 | 2020-09-24 | Kura Oncology, Inc. | Methods of treating cancer patients with farnesyltransferase inhibitors |
| WO2021126729A1 (en) | 2019-12-17 | 2021-06-24 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| EP4303246A1 (de) | 2022-07-04 | 2024-01-10 | Covestro Deutschland AG | Polyisocyanatgemisch |
| CN120917311A (zh) | 2023-03-02 | 2025-11-07 | 卡西蒙生物技术有限责任公司 | 用于诊断癌症和/或急性炎性疾病的手段和方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2492372A1 (fr) * | 1980-10-21 | 1982-04-23 | Cird | Dihydroxy-1,8 anthrones-9 substituees en position 10 et leur utilisation en medecine humaine ou veterinaire et en cosmetique |
| NZ275691A (en) * | 1993-11-05 | 1998-03-25 | Warner Lambert Co | Di and tripeptides and compositions thereof which inhibit farnesyl transferase |
-
1995
- 1995-07-10 FR FR9508296A patent/FR2736641B1/fr not_active Expired - Fee Related
-
1996
- 1996-07-03 MA MA24302A patent/MA23929A1/fr unknown
- 1996-07-04 PE PE1996000510A patent/PE11898A1/es not_active Application Discontinuation
- 1996-07-05 TW TW085108158A patent/TW438792B/zh not_active IP Right Cessation
- 1996-07-08 ES ES96924952T patent/ES2139373T3/es not_active Expired - Lifetime
- 1996-07-08 PL PL96324430A patent/PL324430A1/xx unknown
- 1996-07-08 US US08/981,840 patent/US5936097A/en not_active Expired - Fee Related
- 1996-07-08 EP EP96924952A patent/EP0839133B1/fr not_active Expired - Lifetime
- 1996-07-08 MX MX9800262A patent/MX9800262A/es not_active IP Right Cessation
- 1996-07-08 BR BR9609440A patent/BR9609440A/pt not_active Application Discontinuation
- 1996-07-08 IL IL12281296A patent/IL122812A/en not_active IP Right Cessation
- 1996-07-08 CN CN96195415A patent/CN1096448C/zh not_active Expired - Fee Related
- 1996-07-08 WO PCT/FR1996/001062 patent/WO1997003050A1/fr not_active Ceased
- 1996-07-08 KR KR1019980700157A patent/KR19990028856A/ko not_active Ceased
- 1996-07-08 DE DE69604588T patent/DE69604588T2/de not_active Expired - Fee Related
- 1996-07-08 DK DK96924952T patent/DK0839133T3/da active
- 1996-07-08 UY UY24276A patent/UY24276A1/es not_active IP Right Cessation
- 1996-07-08 CA CA002224414A patent/CA2224414A1/fr not_active Abandoned
- 1996-07-08 CZ CZ199854A patent/CZ291620B6/cs not_active IP Right Cessation
- 1996-07-08 JP JP9505557A patent/JPH11511123A/ja active Pending
- 1996-07-08 AU AU65224/96A patent/AU712194B2/en not_active Ceased
- 1996-07-08 AT AT96924952T patent/ATE185341T1/de not_active IP Right Cessation
- 1996-07-08 NZ NZ313211A patent/NZ313211A/xx unknown
- 1996-07-08 SK SK26-98A patent/SK282250B6/sk unknown
- 1996-07-08 EA EA199800118A patent/EA000797B1/ru not_active IP Right Cessation
- 1996-07-09 TN TNTNSN96098A patent/TNSN96098A1/fr unknown
- 1996-07-10 MY MYPI96002848A patent/MY114792A/en unknown
- 1996-07-10 ZA ZA965868A patent/ZA965868B/xx unknown
- 1996-07-10 AR ARP960103511A patent/AR003143A1/es unknown
- 1996-07-10 CO CO96036152A patent/CO4700457A1/es unknown
-
1998
- 1998-01-09 NO NO980094A patent/NO309565B1/no unknown
-
1999
- 1999-10-07 GR GR990402001T patent/GR3031409T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA965868B (en) | Farnesyl transferase inhibitors their preparation and pharmaceutical compositions comprising them | |
| ZA965750B (en) | Farnesyl transferase inhibitors their preparation and pharmaceutical composition comprising them | |
| ZA961072B (en) | New farnesyl transferase inhibitors their preparation and the pharmaceutical compositions which contain them | |
| ZA961073B (en) | New farnesyl transferase inhibitors their preparation and the pharmaceutical compositions which contain them | |
| NZ305254A (en) | Farnesyl protein inhibitors and pharmaceutical compositions thereof | |
| ZA96258B (en) | New farnesyl tranferase inhibitors their preparation and the pharmaceutical compositions which contain them | |
| HUP9900185A3 (en) | Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives, their preparation, pharmaceutical compositions containing them and their use | |
| IL133470A0 (en) | Inhibitors of farnesyl protein transferase and pharmaceutical compositions containing same | |
| IL116851A (en) | 3-arylidene-2-oxindole derivatives and pharmaceutical compositions containing them | |
| IL119466A0 (en) | Thrombin inhibitors their preparation and pharmaceutical compositions containing them | |
| IL117860A0 (en) | Substituted 1-phenyl-3-pyrazolecarboxamides their preparation and pharmaceutical compositions containing them | |
| IL124801A0 (en) | Pyrazole derivatives their preparation and pharmaceutical compositions containing them | |
| IL107587A0 (en) | Farnesyl derivatives and pharmaceutical compositions containing them | |
| IL122293A0 (en) | Substituted 4-phenylaminothiazoles their preparation and pharmaceutical compositions containing them | |
| IL114925A0 (en) | Glycinamide derivatives their preparation and pharmaceutical compositions containing them | |
| IL119559A0 (en) | Purin -6- one derivatives their preparation and pharmaceutical compositions containing them | |
| IL115905A0 (en) | Sordarin derivatives their preparation and pharmaceutical compositions containing them | |
| HUP0203054A3 (en) | Farnesyl protein transferase inhibitors, pharmaceutical compositions containing them and their use | |
| IL117554A0 (en) | Imidazoquinazolines their preparation and pharmaceutical compositions containing them | |
| ZA967800B (en) | Heteroaryllsubstituted acryloylguanidine derivatives and pharmaceutical compositions comprising them | |
| HUP9602196A2 (en) | Sulfonyl- and sulfinyl-benzoyl-guanidine derivatives and pharmaceutical compositions thereof | |
| IL117397A (en) | Substituted naphthyl compounds and pharmaceutical compositions comprising them | |
| IL116825A0 (en) | Vitamin d derivatives their preparation and pharmaceutical compositions containing them | |
| IL119371A0 (en) | Sulfonylaminopyrimidines their preparation and pharmaceutical compositions containing them | |
| IL118672A0 (en) | Benzisothiazolyl-substituted aminomethylchromans their preparation and pharmaceutical compositions containing them |